Ebola virus (EBOV) haemorrhagic fever remains a threat to global public health with an urgent need for an effective treatment. In order to achieve these goals, access to non-human primate (NHP) laboratory models is an essential requirement. Here, we present the first NHP-EBOV laboratory model readily available to the European scientific community, based on infection of Mauritian cynomolgus macaques using a Central-African EBOV strain and increasing virus challenge dose (10, 100, or 1000 focus forming units per animal). The outcome of these experiments was assessed using clinical, hematological, and biochemical criteria. All challenge doses resulted in fatal infections within 8e11 days. Symptoms appeared from day 5 after infection onwards and disease progression was slower than in previous reports based on Asian cynomolgus macaques. Thus, our model resembled human disease more closely than previous models (onset of symptoms estimated 2e21 days after infection) extending the period of time available for therapeutic intervention. To establish the dynamics of virus genome variation, the study included the first detailed analysis of major and minor genomic EBOV variants during the course of the disease. Major variants were scarce and the population of minor variants was shaped by selective pressure similar to genomic mutations observed in Nature. This primate model provides a robust baseline for future genomic studies in the context of therapeutic methods for treating Ebola virusinfected patients.
Introduction
Non-human primate (NHP) models are an essential requirement for the study of viral haemorrhagic fevers such as those caused by Ebola virus. Indeed, without such in vivo methods and appropriate maximum containment BSL4 laboratory facilities, vaccine candidates and potential antiviral treatments cannot be developed safely or validated for use in humans. Previous studies on Ebola virus (EBOV) have used either rhesus macaques (Macaca mulatta) (Ebihara et al., 2011; Fisher-Hoch et al., 1985) or cynomolgus macaques (Macaca fascicularis, also named "Long-tailed" or "Crabeating" macaques) from Asia (Geisbert et al., 2003; Marzi et al., 2015; Qiu et al., 2012) .
Macaca fascicularis is one of the most commonly used NHPs in academic research, but population genetic research has revealed significant substructure throughout the species distribution that may lead to distinct phenotypic traits which could confound scientific studies (Ogawa and Vallender, 2014) . Accordingly, it was important to characterize as completely as possible our EBOV infection model using a known homogeneous sub-population of macaques, potentially overcoming variability as seen in previous experiments performed with macaques presumed to be from a variety of Asian sub-populations.
Accordingly, we present here the first experiments using an NHP model of Ebola virus disease in a European maximum containment (BSL4) laboratory facility (Laboratoire P4 Jean M erieux, Lyon, France). We used the Zaire EBOV virus strain, as described in a number of previously reported experiments (Ebihara et al., 2011; Geisbert et al., 2003; Marzi et al., 2015; Qiu et al., 2013) , as the challenge virus and cynomolgus macaques known to have been resident in Mauritius for approximately 400 years (Lawler et al., 1995) , following their introduction presumably from a Sumatran sub-population (Tosi and Coke, 2007) .
Intramuscular injections of 10 focus-forming units (ffu), 100ffu or 1000ffu of EBOV were administered, with follow-up of clinical, hematological, biochemical and viral load analyses.
In addition, we present the first analysis of virus population variation during the course of Ebola virus infection. This was achieved by systematic quantified next-generation sequencing and characterization of variants at different stages of infection. EBOV genomic variability was characterized and the information gained will support future experimental studies aimed at developing antiviral therapeutic intervention.
The results of this study will bring to the attention of the European research community the availability of the necessary facilities and protocols with which to extend our capability of developing methods for controlling Ebola haemorrhagic fever.
Materials and methods

Study design
The NHP experiments were performed using cynomolgus macaques (Macaca fascicularis) obtained from a Mauritian colony known to be free of herpes B-virus, tuberculosis, simian T-cell leukemia virus and simian type D retrovirus. Prior to the study the animals were quarantined by Silabe ADUEIS (Strasbourg, France). All experiments were performed in the Inserm-Jean M erieux laboratory BSL4 facilities in Lyon.
The study was conducted using twelve female NHPs (3 years old, weight range 3.5e5.0 kg), housed and monitored in accordance with the guidelines of the European directive 2010/63 and procedures established for use of animals in BSL4 facilities. The primates were anaesthetized via intramuscular injection using Zoletil ® (Tiletamine/Zolazepam w/w, 3 mg/kg) and infected by intramuscular injection in the right leg quadriceps of a titrated supernatant fluid containing the Ebola virus Gabon 2001 strain (a Central African strain of EBOV). The primates were divided into 3 groups of 4 animals which were infected with either 10 focusforming units (ffu), 100ffu or 1000ffu of EBOV, respectively. The experimental protocol received ethical authorization number P4-2014-008 (18th of November 2014, CECCAPP C2EA15 ethical committee, registered with the French Ministry of Research).
Clinical follow-up, sampling and euthanasia score
(i) Body temperature and weight were measured at days 0, 2, 5 post-infection (pi) and every day when clinical signs indicated progression of disease. All results were expressed as change from day zero. (ii) Blood collection in the femoral vein under anaesthesia was collected for most of the monkeys at days 0, (before infection the same day), 2, 5 and 7 pi. Additional samples were collected between days 8 and 11 pi on surviving animals. (iii) Scoring for disease progression was performed daily from day 7 pi, using the following parameters: temperature, increase or decrease of food and water intake, weight loss, dehydration, hemorrhage, and rash. A score !15 (Table S1) was the criterion for euthanasia (performed by intra-cardiac administration of 5 mL of pentobarbital under anaesthesia).
Necropsy was performed for all animals.
Biochemical and hematological follow-up
Serum levels of enzymes (ALP, ALT), creatinine, urea, and C Reactive Protein (CRP) were estimated using a Pentra C200 Analyzer (Horiba, Kyoto, Japan) at days 0, 2, 5 and 7 pi. Total leukocyte, lymphocyte, platelet and erythrocyte counts, haemoglobin and hematocrit values were determined from EDTA-treated blood samples using the MS9-5s Hematology Analyzer (Melet Schloesing, Osny, France) at days 0, 2, 5, 7, 9 pi (except for monkey CB821 which died on day 8 pi) at day 10 and day 11 pi in surviving monkeys. All results were expressed as change from day 0.
Virological follow-up
Molecular viral load
A synthetic RNA template, including the envelope gene region targeted by the Gibb system (Gibb et al., 2001 ) was produced using the MEGA shortscript™ T7 Transcription Kit (Thermo Fisher Scientific) and quantified by spectrophotometry. EBOV genomic RNA was detected in NHP plasma samples by real time RT-PCR using the Gibb system and the GoTaq Probe one step qRT-PCR kit (Promega) following manufacturer's instructions. Quantification was performed with reference to the standard curve obtained from serial dilutions of the standardized synthetic RNA template. Molecular viral load was assessed at days 0, 2, 5, 7 and 9* pi (*day 8 pi for monkey CB821), occasionally at day 10 pi and day 11 pi in surviving monkeys.
Infectious virus titer
Virus titre in blood was determined using 12-well microplates of Vero E6 cells. Cells were incubated with serial dilutions of plasma (1 h, 37 C), then grown in the presence of carboxy-methylcellulose (37 C, 7 days). Infectious foci were detected by incubation with a GP EBOV specific monoclonal antibody (generously provided by Laurent Bellanger and Fabrice Gallais, LI2D Laboratory, CEA, Marcoule, France), followed by phosphatase-conjugated polyclonal anti-mouse IgG and 1-step NBT/BCIP plus Suppressor (Thermo Fisher Scientific). Virus titre was expressed as focusforming units (ffu) per millilitre of plasma. Infectious viral loads were measured in serum samples at days 0, 2, 5, 7 and 9* pi for all monkeys (*day 8 pi for monkey CB821), occasionally at day 10 and day 11 pi in surviving monkeys.
Next-generation sequencing
Virus sequencing from clinical samples was performed directly without virus isolation in cell culture. Viral RNA was extracted from serum using the QiaCube HT device and Cador Pathogen kit (Qiagen). Eight overlapping amplicons spanning the complete genome sequence were produced from the extracted RNA using the SuperScript ® III One-Step RT-PCR System with Platinum ® Taq High Fidelity kit (Thermo Fisher Scientific) and specific primers. PCR products were pooled in equimolar proportions for library building. Sequencing was performed using the PGM Ion torrent technology (Thermo Fisher Scientific) following manufacturer's instructions. Automated read datasets provided by Torrent software suite 5.0.2 were trimmed according to quality score (99%) and length (reads shorter than 30bp were removed) using CLC genomics workbench software (CLC bio-Qiagen). Primers used for RT-PCR were removed using an in-house software package. Reads were mapped on reference (inoculum strain) using CLC. A de novo contig was also produced to ensure that the consensus sequence was not affected by the reference sequence. Substitutions with a frequency higher than 1% (minor variants: variants frequency >1% and <50%) were considered for further analysis. Detailed protocols for extraction, amplification and sequencing are provided in supplemental data.
Distribution of variants at synonymous and nonsynonymous sites: The distribution of identified variants at synonymous and non-synonymous sites was compared with an in-house model providing random distribution of the same number of variant sites in EBOV coding regions after 1000 simulation replicates (see supplemental data for details describing the model).
Distribution of major variant sites with reference to GenBank full-genome sequences: We compared the genomic distribution of minor variants identified in infected NHPs, with that of major mutations (frequency !50%) reported in GenBank Ebola Zaire genomic sequences (212 sequences). The number of common variant sites was determined for variants at 1%, 3%, 5% and 10% and compared with the number of common variant sites expected under a regimen of random distribution (see supplemental data for details concerning statistical analysis).
Sequencing of the batch inoculum produced in Vero cells (strain EBOV Gabon 2001) was performed by extraction of the RNA from clarified supernatant medium. It was reverse transcribed, amplified, sequenced and analyzed as described above. A complete EBOV genome sequence was obtained after mapping the reads against EBOV Gabon 2002 strain reference (GenBank KC242800, Zaire ebolavirus isolate EBOV/H.sapiens-tc/GAB/2002/Ilembe).
Plasmid controls: Two plasmid regions located in the NP gene and L gene of 2178 (residues 494e2671) and 3,039bp (residues 11,606e14,644) respectively were amplified using the SuperScript ® III One-Step RT-PCR System with Platinum ® Taq High Fidelity kit (Thermo Fisher Scientific) and fully sequenced as described above. Minor variants were analyzed to evaluate the background noise due to the sequencing method.
Statistical analyses
Distribution of genomic variants was studied using the chi2 test and binomial analysis. Comparison of non-paired series was performed using the Wilcoxon test. Statistical analyses were performed using R software.
Results
Disease progression
All infected animals died or were euthanized between days 8 and 11 pi ( Fig. 1A and B ). In the 10ffu group, three animals (10ffu-CB633, 10ffu-CB661 and 10ffu-CB145) developed severe HF (haemorrhagic fever) with gingivorrhagia, skin rash, anorexia and severe diarrhea. They reached the critical clinical score for euthanasia on day 11, 10 and 11 pi, respectively. The fourth monkey (10ffu-CA954) was found moribund with anorexia and severe diarrhea at day 10 pi.
In the 100ffu group, one animal (100ffu-CA952) developed severe HF with skin rash and anorexia and reached critical clinical score for euthanasia on day 9 pi. Two animals (100ffu-CA881 and 100ffu-CB748) were found moribund with anorexia and severe diarrhea at day 9 pi. The last monkey (100ffu-CB760) was found dead, after a single diarrhea episode, at day 11 pi.
In the 1000ffu group, two animals (1000ffu-CB118 and 1000ffu-CB821) developed severe HF with gingivorrhagia, skin rash, anorexia and severe diarrhea. They reached the critical clinical score for euthanasia on day 9 and 8 pi, respectively. One animal (1000ffu-CB829) was found moribund at day 9 pi with anorexia and severe diarrhea. The last monkey (1000ffu-CC089) was found dead at day 11 pi.
Evolution of body temperature and weight are reported in Fig. 1C and D. All animals showed a decrease in food intake by day 6 pi and a cessation of food intake by day 7 pi. For all groups, the median weight slightly increased during the first 2 days. At day 5 pi, it still increased for the 10ffu and 100ffu groups, but started decreasing for the 1000ffu group. Subsequently, weight decreased in all groups with a final weight loss of 5e8% in all groups (see Table 1A ). The weight loss at day 7 pi was significantly lower in the 10ffu group than in other groups (Wilcoxon test, p ¼ 0.017). Raw data are presented in Supplementary Table S4 . Regarding temperature variations, the median values increased at day 2 pi for the 10ffu and 100ffu groups, whereas a decrease was observed for the 1000ffu group. The temperature then increased in all groups reaching higher than 39 C by day 7 pi. It decreased only in the 100ffu group on day 9 pi (see Table 1B ). Raw data are presented in Supplementary Table S5 .
Viral loads
Viremia became detectable on day 5 pi for 10 monkeys and on day 2 pi for 2 monkeys (from the 10ffu and 1000ffu groups) (Fig. 1E ). The molecular viral load peaked at day 7 pi, with median (range) values of 10 8.14 genomes/mL (10 7.65 -10
), 10 9.66 (10 8.9 -10 10 ) and 10 9.18 (10 8.9 -10 9.22 ) for the 10ffu, 100ffu and 1000ffu groups, respectively (Fig. 1E ). Raw data are presented in Table S6 . Infectious viral loads were detectable at day 5 pi and peaked at day 7 pi, with median (range) ) for the 10ffu, 100ffu and 1000ffu groups, respectively (see Fig. 1F and Table S7 ).
Blood chemistry and hematology
Raw biochemical data can be found in Table S8 . The creatinine and urea values were quite stable, with only one (creatinine) and two (urea) monkeys showing late elevated values, respectively ( Fig. 2A and B ). An important rise in CRP level (denoting high level of inflammation) was observed from day 5 pi in all monkeys except one (belonging to the 1000ffu group). On the other hand, CRP levels decreased in 3 monkeys that survived more than 9 days pi (Fig. 2C) .
No relevant rise of ALT or ALP serum levels was observed during the course of the disease, except at day 7 pi (mostly in the 100ffu and 1000ffu groups) ( Fig. 2D and E) .
Raw hematology data can be found in Table S9 . Hematocrit values were highly heterogeneous, with a moderately decreased trough value at day 7 pi (median variations: À6.3%, À6.8% and À3.8% for the 10ffu, 100ffu and 1000ffu groups, respectively) (Fig. 2F) . A severe, early and continuous decrease of the platelet count was observed in all groups (median decrease values: À145 10 3 , À141 10 3 ,-102 10 3 platelets/mm 3 at day 9 pi (day 8 pi for CB821), for the 10ffu, 100ffu and 1000ffu groups, respectively) ( Fig. 2G ). WBC count, monocyte, basophil and neutrophil proportion values were heterogeneous without any marked evolutionary trend (Fig. 2HeK) . By contrast, the eosinophil proportion increased and the lymphocyte proportion decreased in all groups until day 7 pi (Fig. 2L and M).
Next-generation sequencing
In the absence of previous experimental datasets deciphering the genomic evolution of Ebola virus during the different stages of infection, we attempted to provide answers to the following basic questions: does the genetic diversity observed in blood increase over time and can it be characterized (occurrence of majority and 10 ffu-CB145 100 ffu-CA952 100 ffu-CB760 100 ffu-CA881 100 ffu-CB748 1000 ffu-CB821 1000 ffu-CB829 1000 ffu-CB118 1000 ffu-CC089 Table 1 Median (range) change of weight (A) and body temperature (B) from day 0, according to the inoculum dose. * for some monkeys measurements were available at day 8 pi and not day 9 pi. Data are displayed as figure in Fig. S1 . For this purpose, complete EBOV genome sequences (except the 5 0 and 3 0 primers, i.e., 18,871 nucleotides (nt)) were obtained for the viral isolate (EBOV Gabon 2001) used for monkey inoculation, and for all twelve monkeys at days 5, 7 and 9* pi (*day 8 pi for CB821) (except for one monkey with a low viral load at day 5 pi in the 1000ffu group).
The mean (range) number of reads per position for all sequences was 23,704 reads/position (5610e79,697), with similar profiles along the genome for all sequences (supplemental data Fig. S2 ). All the information concerning the raw data and GenBank submission is summarized in Table S10 .
Plasmid control
To control the "background noise" generated via the sequencing protocol, two EBOV plasmids were sequenced using the same protocol. No mutations present at a frequency higher than 1% could be detected. This validated the 1% detection of minor variants as a relevant threshold for quasi species analysis of viral sequences.
Virus inoculum
Reads obtained from strain EBOV Gabon 2001 were mapped onto the Genbank sequence KC242800 (Zaire ebolavirus isolate EBOV/H.sapiens-tc/GAB/2002/Ilembe). Eight fixed mutations differentiating the two strains were identified (Table S11 ). The distribution of minor variants (frequency >1%) is presented in Fig. 3 . Five mutations (all with frequencies <2%) were detected in non-coding regions (NCR): 3 in the 3 0 NCR, 1 in the VP30-VP24 intergenic NCR and 1 in the 5 0 NCR. In the coding sequence, 8 mutations were identified along the GP gene and 3 in the L gene (all with frequencies <3.5%). All details regarding the list of variants and their respective frequencies are presented in Table S11 .
3.4.3. Monkey sera 3.4.3.1. Major variants sites. Viral reads from monkey sera were mapped using the inoculum sequence as a reference. In the complete dataset comprising all sequences produced from monkeys, only four major variants could be detected throughout the viral genome (Table 2A) . No insertions or deletions were detected. Three minor variants induced ORF modifications, introducing premature stop codons or modifying a start codon (Table 2B) .
3.4.3.2. Minor variant sites. Deep sequencing coverage enabled the identification, in the complete dataset of 35 EBOV complete genomes from monkey sera, of a total of 822 variant sites with a frequency >1%. (The nature and type of minor variant by monkey is presented in Table S20 ). The mean number of minor variant sites (frequency >1%) per monkey was calculated as the total number of distinct variant sites in the group considered (e.g., for samples collected at day 5 pi) divided by the number of monkeys studied. The same variant site appearing in different samples was counted once.
It was found to be similar at days 5 and 7 pi (34.1 and 31.9 variants/monkey, respectively), and higher at day 9 pi (40.1 variants/monkey) (Fig. S3) . No clear difference according to the inoculum group (10-100-1000ffu) was observed. The variant site distribution is shown for each individual monkey in Fig. 4 .
In the complete dataset, variant sites in NCRs were significantly over-represented (5.6/100 nt, vs 4.0/100 nt in coding regions, p ¼ 3 10 À6 , chi-2 test) (Fig. S4 ). Genomic regions with the highest numbers of variant residues were: 5 0 NCR (7.7% of positions found to be variant at least once) > GP/VP30 (6.4%)
). Details are presented in supplemental data, Table S13 . The proportion of transitional mutations at variant sites was 82%. It was quite constant over time during infection (80e83%), and similar in the different inoculum groups (80e86% , Table S14 ). In coding regions, 41% of all mutations were synonymous. This proportion was clearly higher than that (22%) obtained in a random distribution of 568 variants (the number actually observed in the complete dataset) in coding regions of the genome. It was quite stable over time (41%e47%) and in the different inoculum groups (39e45%).
Ten variant sites identified in the inoculum strain were found amongst the variant sites reported from monkey sera (Table S12) . Seventy-two variant sites (9%) were identified in at least two different monkeys (distribution detailed in Table S19 ).
The distribution of mutations per monkey and per sampling day is shown in Fig. S5 and reveals that 133 variant sites were repeatedly identified at days 5, 7 and 9* pi (*day 8 pi for monkey CB821); 265 were observed at least on two different days in the same animal (Fig. S6) . Again, these repeatedly variant sites were statistically over-represented in non-coding regions (p ¼ 6 10
À4
, chi-2 test). They represent 31% of all variant sites in coding regions, and 36% of all variant sites in non-coding regions. All details regarding repeatedly variant sites can be found in supplemental data Table S15 .
We investigated the distribution of minor variants in the genome with reference to variant sites (fixed mutations) observed in complete genomic sequences of Zaire Ebola virus deposited in Genbank. Amongst the 18,871 positions of the genome analyzed, 1627 were variant in at least one Genbank sequence. Amongst these 18,871 genomic positions, 226, 308 and 822 were mutated with frequency >5%, 3% and 1%, respectively. When we identified variant sites shared by GenBank sequences and by our minor variants, we observed that the ratio (observed number of common sites/expected number of common sites in case of random distribution) was 1.55, 1.51 and 1.50 for variants with frequency >5%, 3% and 1%, respectively. The excess of common variant sites with reference to a random distribution was significant upon binomial analysis for variants with frequency >5%, 3% and 1% (p ¼ 0.02, 0.01 and 8 10 À5 , respectively) (Table S16 ). For variants with frequency >10%, the ratio (observed number of common sites/expected number of common sites) was 1.42, but low numbers (106 variant sites only) resulted in failure to reach statistical significance.
Variants.
In the previous section, we analyzed the number of distinct variant sites. Here we performed a more detailed analysis by taking into account the frequency of mutations at each variant site. This was achieved by defining the "volume of variant nucleotides" per genome. For example, if 30 variants per genome were reported with a mean frequency of 5% for each variant, the global "volume" of variant nucleotides would be 1.5nt/genome (30 Â 0.05, i.e., the product of the number of variants by the mean frequency of all variants). This volume per genome can be further modulated to take into account the viral load. In the above mentioned example, with a viral load of 10 5 genome copies per mL of serum, the "volume of variant nucleotides" per mL of serum would be 1.5 10 5 nt/mL (30 Â 0.05 Â 10 5 , i.e., the product of the volume of variant nt/ genome by the number of genome copies/mL). This means that the final extent of nt variability observed in the blood of infected macaques was modulated by three parameters which do not evolve in parallel, i.e., the number of variants, the frequency of these variants Table S17 . Of note, this calculation started with the number of variant sites identified in each individual sample analyzed: when mean values were calculated using different samples, the same variant sites appearing in different samples were counted as many times as they occurred. Results are similar to those reported in the previous section, based on distinct variant sites, with maximum values being observed at day 9 pi* (*day 8 pi for CB821).
Regarding the mean variant frequency values (per inoculum group and per day), the global trend observed was a slight decrease over time without marked difference according to the inoculum dose. The maximum value was observed at day 5 pi in all groups (Table S17) .
Regarding the mean volume of variant nt/genome, (per inoculum group and per day), the minimum value was observed at day 7 pi in all groups (Table S17), without marked difference according to the inoculum dose.
Regarding the volume of variant nt/mL of serum, the values were higher for the 100ffu group than for the other groups (Wilcoxon test: day 5 pi: p ¼ 0.11; day 7 pi: p ¼ 0.061; day 9 pi: p ¼ 0.033). Furthermore, the maximum mean volume of variant nt/ mL of serum was reached at the peak of viremia. Of note, despite maximum values for the number of variant sites being observed at day 9* pi (*day 8 pi for CB821), the mean final volume of variant nt/ mL at day 9 pi was low due to an important decrease of the viral load at this time (Fig. 5) .
The frequency of variants was slightly higher in non-coding than in coding sequences. However, the final volume of variants/genome was higher in coding regions, due to the higher number of variant sites in these regions (Table S18 ).
The frequency of transition and transversion variants was similar. However, the final volume of transitions/genome was higher, due to the higher number of sites associated with transition substitutions (Table S18) .
The frequency of synonymous and non-synonymous variants was similar. However, the final volume of non-synonymous variants/genome was slightly higher, due to the higher number of sites associated with non-synonymous substitutions (Table S18) .
Discussion
We have successfully established a non-human primate animal model for Ebola virus using (i) Mauritian cynomolgus macaques; (ii) a Central African Ebola virus strain; (iii) the intra-muscular route for inoculation; (iv) multi-dose virus challenge (10, 100 and 1000ffu); (v) euthanasia of the animals according to a clinical score including temperature, weight loss, food and water consumption, dehydration, bleeding, petechial hemorrhages and stools. This model is globally in line with previous ones reported in the literature, conducted either with Asian cynomolgus macaques (FisherHoch et al., 1992; Qiu et al., 2012) or rhesus monkeys (Ebihara et al., 2011; Fisher-Hoch et al., 1985) . However, as far as we know, this is the first time that Mauritian cynomolgus macaques were used for Ebola infection trials. It is therefore important to consider the characteristics of the Ebola virus infection in these specific monkeys and how clinical and biological markers can be used for the follow-up of infection.
First, the model proved to be lethal in all monkeys, whatever the inoculum dose used. The weight loss in animals receiving a 10ffu inoculum occurred later and was significantly less acute than in Table 2 EBOV major variants observed in monkey sera (A), and minor variants modifying start and stop codons (B). Mutation T7034A was present as majority variant in the genome of macaque 1000ffu-CA089 at day 5 pi (D5), and present as a minor variant in the genome of macaque 1000ffu-CB829 at day 7 and 9 pi (D7 &D9)*. NS: Non Synonymous; S: Synonymous. other groups. There was a trend towards longer survival in animals that received the lowest inoculum (10ffu). This agrees with a previous report (Geisbert et al., 2002) . Clinical presentation was in agreement with what has been described previously in Ebola virus infected macaques, including fever, reduction of activity, appetite, weight loss and hemorrhage. Regarding biological markers, viremia appeared most frequently at day 5 pi, peaked at day 7 pi and decreased afterward, proving to be a reproducible follow-up parameter. This was also the case of some inflammation (C-Reactive Protein), and hematological markers (lymphopenia, thrombocytopenia, hematocrit decrease and increase of eosinophils) which were clearly associated with the course of infection. By contrast, the kinetics of hepatic and kidney markers (transaminases, creatinine and urea) showed limited and late variations.
One of the most striking observations relates to the overall kinetics of the disease in Mauritian macaques, which is somewhat slower than that reported in other NHP models. In previous studies, death occurred 1e2 days earlier (Ebihara et al., 2011; Qiu et al., 2012 ) than in our model, and fever or weight loss were also detected 2e3 days earlier (Marzi et al., 2015; Qiu et al., 2012) . Similarly, the peak of viral load (Marzi et al., 2015; Qiu et al., 2012) and the deterioration of hematological parameters (Marzi et al., 2015; Qiu et al., 2012) commonly occurred 1e2 and 3e4 days earlier than in our model, respectively. The kinetics of infection is therefore more similar to what is observed in humans (symptoms appear from 2 to 21 days after infection) and this could be advantageous and relevant for testing antiviral therapeutic interventions. It offers a wider time range for starting therapy at different stages of the infection period.
A specific aspect of this study was the detailed analysis of virus genomics at different stages of viremia using next-generation sequencing. This is an important aspect since very limited information regarding the evolution of the virus during the course of the disease is available from the scientific literature. We tried to provide a first descriptive analysis of majority and minor variants and to characterize in more detail a possible genetic adaptation process, the effect of the inoculum dose on observed virus variability, and the relationship between genomic variability and the kinetics of virus replication.
The first information of interest is that major variants (i.e., mutations that become the majority nucleotide detected at a given position in a blood sample) were very rare. Such mutations were observed in only four instances ( Fig. 2A) , once in the 5 0 non-coding region, twice in the glycoprotein gene (producing a Y333N and a R130Q amino acid changes in the GP) and once in the polymerase gene (synonymous substitution). Of note, none of these mutations was completely fixed during the evolution period since their maximum frequencies amongst virus variants were 51%, 81%, 57% and 58%, respectively. It can be concluded that the infection of macaques by a strain produced in Vero cells does not spontaneously lead to a rapid and acute viral adaptation process.
More information was retrieved from the analysis of minor variants, which were detected and quantified when their frequency was above 1%. We observed that the frequency of minor variants was significantly higher in non-coding regions than in open reading frames. This was true when analysis focused on the number of mutated sites, or on the "volume of mutations" (that takes into account the frequency of minor variants). By contrast, no dose effect was detected, i.e., no relationship between the number, volume and distribution of minor variants and the infectious dose was identified.
Remarkably, the same minor variants were commonly observed at different time points for a given animal (32% and 16% of the total number of variant sites were respectively identified at two or three time points) and 9% of variant sites were observed in at least two different animals. Some variants detected in the inoculum strain were identified in the blood of infected macaques at days 5, 7 and 9 pi. When we compared the distribution in the viral genome of minor variants identified in infected macaques with the spectrum of variant sites (fixed mutations) observed in complete genomic sequences of Zaire Ebola virus deposited in Genbank, we observed a significant excess of common variant sites with reference to a random distribution. This suggests that similar evolutionary constraints operate for the selection of some minor variants and fixed mutations. In other words, a proportion of the fixed mutations observed in nature in Zaire Ebola virus strains exists in the form of minor variants in the virus population of infected macaques. Similarly, the excess of minor variant sites detected in non-coding regions of the genome had previously been observed amongst fixed mutations identified in Ebola virus genomes (Jiang et al., 2015) .
Our analysis of the nature of substitutions indicated that transitions were more frequent than transversions, but also that, in coding regions, the proportion of synonymous variants was higher than that expected under a regimen of random distribution. This is evocative of a purifying selection process operating at the level of the population of minor variants with frequency over 1%. Regarding the kinetics of minor variants overtime, the maximum number of variant sites was reached at day 9 pi, i.e. two days after the peak of viremia. It can be hypothesized that at day 7 pi the maximum replication level is reached by the expansion of a nearly clonal population replicating with a high fitness in primary target cells. During the following days, after infection of a majority of primary target cells, virus production decreases and variation in sequences may correspond to increased replication in secondary target cells. However, possibly due to the short course of the disease or to the variety of secondary target cells, this does not produce the emergence of fixed mutations and clearly identified high fitness mutants (see above). This may be further tested in the future by performing at different time points organ-specific virus genomics and viral load studies.
In conclusion, we have achieved a complete description of the clinical, virological, biochemical and hematological characteristics of an Ebola virus infection model in Mauritian cynomolgus macaques, which revealed some interesting characteristics. For example, the kinetics of infection close to what is observed in humans and this may be advantageous for testing therapeutic interventions. These experiments and the subsequent analyses also provide the first study detailing Ebola virus genomic evolution in primates, based on next-generation sequencing and including the analysis of minor variants in viral populations. It should provide the necessary baseline for future genomic studies performed in the context of experimental therapeutic interventions. In conclusion, we have developed (in the P4 INSERM Jean M erieux laboratory) the first Ebola virus infection model in non-human primates which will be readily available to the European scientific community. This will enable the subsequent development of a variety of scientific programs in the field of Ebola antiviral therapy and vaccines. It is anticipated that such programs will significantly contribute to current efforts aimed at generating efficient preventive measures and therapeutic treatments of Ebola virus infection.
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